Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Common contraindications cited in the research-use community include: anyone with active or recent cancer (BPC-157 and TB-500 promote angiogenesis), people with Wilson's disease or other copper-metabolism disorders (GHK-Cu component), anyone pregnant or breastfeeding (no safety data), and athletes subject to WADA testing (BPC-157 and TB-500 are prohibited)
Injections are best for: Severe deficiencies, pernicious anemia, significant malabsorption issues, and when rapid symptom relief is needed
In addition, when compared head to head with PRP, its effects are similar
What Makes MOTS-C Unique
Antioxidant activities: According to France research, engineered Lactococcus lactis as a delivery vehicle for BPC-157 demonstrates antioxidant activity, reducing ROS production in cell models (5)
A pilot study on intraarticular knee pain found that 7 of 12 patients reported improvement lasting six or more months
US$ 28.12
US$ 27.64
US$ 24.09
US$ 22.10
US$ 23.80